Peer Review History

Original SubmissionJune 29, 2021
Decision Letter - Muhammad Adrish, Editor

PONE-D-21-21086

The burden of SARS-CoV-2 among healthcare workers across 16 hospitals of Kashmir, India- a seroepidemiological study

PLOS ONE

Dear Dr. Mariya Amin Qureishi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please review the comments made by the reviewers and provide point by point response in the revised manuscript.

Please submit your revised manuscript by September 5th, 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Adrish, MD, MBA, FCCP, FCCM

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Please amend your list of authors on the manuscript to ensure that each author is linked to an affiliation. Authors’ affiliations should reflect the institution where the work was done (if authors moved subsequently, you can also list the new affiliation stating “current affiliation:….” as necessary).

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an important study on a relevant and timey topic. The data would be useful, although we are now past the second wave in formulatng public health policy. I would suggest adding a note on the implications of vaccination status in future studies or longitudinal studies on seroprevalence

Reviewer #2: This study is a cross sectional estimate of COVID seroprevalence based on the nucleocapsid IgG antibody test.

They invited all the level 2 and 3 hospitals in Kashmir. 2 of them refused invitation. From those who agreed to participate, they invited willing hospital staff to enroll.

This serology survey was conducted in January 14 to 17, at a time when first wave had ceased, and Vaccines were yet to be started.

- What is the total number of HCW in each of the hospitals. What % of the staff population accepted to take part in the study?

- why sample size was not calculated?

- Why randomisation was not done?

- What is the mean age of HCWs overall - those included + those refused consent?

- What was the PCR positivity prevalence in those who did not take part?

- Comorbidities have not been captured!

- Was appropriate PPE available for all staff at all times? Did Housekeeping staff get hazmut? A note on the level of preparedness for COVID19 among HCW in Kashmir should be added to help the reader better understand the background.

- Are administrative staff at increased risk of exposure to Clinical areas? Did all the included HCWs work in COVID wards or Emergency services?

- Severity of COVID infection among those who were positive and the Antibody trend at 1,3 and 6 months could have been captured

Overall the study has good data but needs to be presented in a clear way.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Aneesh Basheer

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Reviewer #1: This is an important study on a relevant and timely topic. The data would be useful, although we are now past the second wave in formulating public health policy. I would suggest adding a note on the implications of vaccination status in future studies or longitudinal studies on seroprevalence.

Response: Thank you for your valuable suggestion. It has now been added in the discussion section of the manuscript.

Reviewer #2: This study is a cross-sectional estimate of COVID seroprevalence based on the nucleocapsid IgG antibody test. They invited all the level 2 and 3 hospitals in Kashmir. 2 of them refused the invitation. From those who agreed to participate, they invited willing hospital staff to enroll. This serology survey was conducted from January 14 to 17, at a time when the first wave had ceased, and Vaccines were yet to be started.

What is the total number of HCW in each of the hospitals? What % of the staff population accepted to take part in the study?

Response: Breakup of HCWs in each hospital is tabulated. Overall 40.8% HCWs took part in this study. We have added this information in the manuscript as a supplementary file

Hospital No. of HCWs No. of HCWs participated

District hospital Ganderbal 195 104

District hospital Bandipora 108 85

District hospital Badgam 110 78

District hospital Pulwama 307 100

District hospital Shopiyan 73 64

District hospital Baramulla 174 159

District hospital Kupwara 200 187

District hospital Kulgam 214 77

District hospital Anantnag 206 153

JLNM hospital Srinagar 132 120

SMHS & SS hospital Srinagar 2200 244

Chest disease hospital Srinagar 210 43

Maternity hospital Srinagar 255 142

Bone and Joint hospital Srinagar 215 184

Pediatric hospital Srinagar 217 180

IMHANS hospital Srinagar

95 83

Total 4911 2003 (40.8%)

Why randomisation was not done?

Response: This was a cross-sectional study, so randomization does not apply here. I believe the reviewer is asking about random sampling here. We did not perform a random sampling strategy in this study due to time constraints and practical difficulty.

why the sample size was not calculated?

Response: Our results are based on the voluntary participation of HCWs. Our study included 2003 HCWs and the seroprevalence estimates of 26.8 % with a confidence interval of (24.8- 28.8) show that the estimates have pretty good precision.

- What is the mean age of HCWs overall - that refused consent?

Response: Thank you for your query. The information of those who did not participate in the study was not collected. We have included it in the limitation section of the manuscript.

What was the PCR positivity prevalence in those who did not take part?

Response: Thank you for your query. We did not collect the information of those who did not participate in the study.

Comorbidities have not been captured!

Response: Information about comorbidities was not collected

- Was appropriate PPE available for all staff at all times? Did the Housekeeping staff get hazmat? A note on the level of preparedness for COVID19 among HCW in Kashmir should be added to help the reader better understand the background.

Response: Thank you. Owing to resource constraints, the PPE was not available for all staff at all times. Hazmut was not provided to the housekeeping staff. A note on the level of preparedness has now been added to the methods section.

Our administrative staff at increased risk of exposure to Clinical areas? Did all the include HCWs work in COVID wards or Emergency services?

Response: Since the study was done 10 months after the appearance of the first case of SARS-CoV-2 infection in Kashmir, the level of exposure among all categories of healthcare workers at this time was not much different. All the hospitals had restarted their routine outpatient and inpatient activities. The same is reflected in our study as well. We did not find any difference in the seroprevalence among different occupational categories of HCWs.

Attachments
Attachment
Submitted filename: response to reviewer.docx
Decision Letter - Muhammad Adrish, Editor

PONE-D-21-21086R1The burden of SARS-CoV-2 among healthcare workers across 16 hospitals of Kashmir, India- a seroepidemiological studyPLOS ONE

Dear Dr. Qurieshi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Please review comments made by reviewers and provide response in your revised manuscript.

==============================

Please submit your revised manuscript by October 31st, 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Adrish, MD, MBA, FCCP, FCCM

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In the first review, implications of vaccination was sought. The authors have repsonded by adding a section on this in the discussion. This appears satisfactory and reflects the uncertainty regarding the effect of vaccine induced antibody responses on the seroprevalence among healthcare workers. The paper can be accepted.

Reviewer #2: This study is a cross-sectional estimate of COVID seroprevalence based on the nucleocapsid IgG antibody test. They invited all the level 2 and 3 hospitals in Kashmir. 2 of them refused the invitation. From those who agreed to participate, they

invited willing hospital staff to enroll. This serology survey was conducted from January 14 to 17, at a time when the first wave had ceased, and Vaccines were yet to be started.

Kindly add the reasons provided by the authors for not calculating sample size and convenience sampling in the methodology section.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Aneesh Basheer

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 2

Reviewer #2: This study is a cross-sectional estimate of COVID seroprevalence based on the nucleocapsid IgG antibody test. They invited all the level 2 and 3 hospitals in Kashmir. 2 of them refused the invitation. From those who agreed to participate, they invited willing hospital staff to enroll. This serology survey was conducted from January 14 to 17, at a time when the first wave had ceased, and Vaccines were yet to be started.

Kindly add the reasons provided by the authors for not calculating sample size and convenience sampling in the methodology section.

Response: Thank you for your suggestion. We have now included it in the methodology section of the manuscript.

Attachments
Attachment
Submitted filename: response to reviewer.docx
Decision Letter - Laith Al-Eitan, Editor

The burden of SARS-CoV-2 among healthcare workers across 16 hospitals of Kashmir, India- a seroepidemiological study

PONE-D-21-21086R2

Dear Dr. Qurieshi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Laith Al-Eitan

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thanks for addressing all comments raised by reviewers

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: No revisions were suggested by this reviewer in the previous version. The authors have justified their reason for not calculating sample size raised by the second reviewer.

Reviewer #2: The manuscript in its current form appears to be refined and acceptable for Publication. No further queries from my end.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Aneesh Basheer

Reviewer #2: No

Formally Accepted
Acceptance Letter - Laith Al-Eitan, Editor

PONE-D-21-21086R2

The burden of SARS-CoV-2 among healthcare workers across 16 hospitals of Kashmir, India- a seroepidemiological study

Dear Dr. Qurieshi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Laith Al-Eitan

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .